HMNC Brain Health GmbH raised $50 million in the first close of a Series B financing to move its depression pipeline toward Phase III studies. The capital will enable the company to prepare for late-stage development of two lead programs. The raise comes as mental health biotechs increasingly compete for investor attention by demonstrating regulatory readiness, manufacturing planning, and clear clinical next steps rather than platform-only narratives. For HMNC, the reported intent is specifically to build the path from clinical proof-of-concept into pivotal trials. The financing supports a critical risk-reduction phase for CNS drugmakers: funding Phase III-enabling work, trial execution, and the data package needed for regulatory review.